Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)

4 maggio 2026 aggiornato da: Jennifer Ip, St. Joseph's Healthcare Hamilton

The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.

This study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD/BPD traits).

The main questions this study aims to answer are:

Does GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?

Does GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?

What are participants subjective experience of GE-WET?

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

63

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Canada
    • Ontario
      • Hamilton, Ontario, Canada
        • St. Joseph's Healthcare Hamilton

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Reading and writing proficiency in English
  • Access to an electronic device to attend virtual group meetings
  • Age 18-65
  • Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)/BPD traits
  • Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic

Exclusion Criteria:

  • Diagnosis of an active severe substance use disorder or psychotic disorder
  • Untreated active psychotic symptoms, mania, or hypomania
  • Has attempted suicide in the 2 months prior to treatment beginning
  • Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment
  • Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group Extended Written Exposure Therapy
Participants will be invited to participate in group extended Written Exposure Therapy (described in the Interventions section).
Comportamentale: Group Written Exposure Therapy
Group Extended Written Exposure Therapy (GE-WET) is a time-limited cognitive behavioural therapy for Posttraumatic Stress Disorder (PTSD) aimed at allowing patients to process their traumatic experiences in a safe environment. GE-WET will consist of 10 weekly group sessions. Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
PTSD Checklist for DSM-5 (PCL-5)
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Posttraumatic Cognitions Inventory
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
A 36-item self-report questionnaire that assesses negative thoughts across three subscales: negative cognitions about the self (e.g., "I am a weak person"), negative cognitions about the world (e.g., "I have to be on guard all the time"), and self-blame (e.g., "the event happened because of the way I acted"). The PTCI has demonstrated good internal consistency, test-retest reliability, and convergent validity with other measures of posttraumatic cognitions.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Borderline Symptom List- Short Version (BSL-23)
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The BSL-23 is a 23-item self-report measure that assesses for DSM borderline personality disorder symptomatology as well as associated problems such as self-criticism, loneliness, helplessness, and problems with trust. The BSL-23 has demonstrated high internal consistency and test-retest reliability, and strong convergent validity with correlations with depression and general psychopathology severity.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Borderline Symptom List Behaviour Supplement
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The BSL-23 Behaviour Supplement is an 11-item supplemental measure used to assess frequency of problematic behaviours (e.g., non-suicidal self-injury, suicide attempts, suicidal communication, angry outbursts, misuse of substances, etc.) associated with borderline personality disorder.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Toronto Alexithymia Scale-20 (TAS-20)
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The TAS-20 is a 20-item self-report measure assessing for alexithymia (i.e., issues in identifying and processing emotions) across three factors: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking. The TAS-20 has demonstrated adequate levels of convergent validity, good internal consistency, and good test-retest reliability.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Experience of Shame Scale (ESS)
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The ESS is a 25-item self-report measure assessing characterological shame (e.g., shame of personal habits or personal ability), behavioural shame (e.g., shame in doing or saying something wrong), and bodily shame (e.g., shame regarding one's body). The ESS has demonstrated good internal consistency and test-retest reliability.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Difficulties in Emotion Regulation Scale (DERS)
Lasso di tempo: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The DERS is a widely used 36-item self-report measure assessing six dimensions of emotion regulation difficulties. The DERS demonstrates good internal consistency, convergent validity, and predictive validity of behaviours reflective of emotion regulation difficulties.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Group Cohesion Scale - Revised (GCS-R)
Lasso di tempo: Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
The GCS-R is a self-report measure that measure's group member's perception of their group and the strength of the bonds formed. The GCS-R showed high reliability for use in research and is sensitive to detecting changes in cohesiveness as a function of group development.
Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

St. Joseph's Healthcare Hamilton

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 dicembre 2028

Date di iscrizione allo studio

Primo inviato

20 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

4 maggio 2026

Primo Inserito (Effettivo)

8 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 18906

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Disturbo post-traumatico da stress (PTSD)

Prove cliniche su Group Written Exposure Therapy

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Congo, DR of

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi